<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336283">
  <stage>Registered</stage>
  <submitdate>2/02/2011</submitdate>
  <approvaldate>3/02/2011</approvaldate>
  <actrnumber>ACTRN12611000124932</actrnumber>
  <trial_identification>
    <studytitle>Cognitive changes after saline or Plasmalyte infusion in healthy volunteers: blinded, randomized cross-over trial</studytitle>
    <scientifictitle>A randomised cross-over trial to determine cognitive changes after saline versus Plasmalyte infusion in healthy volunteers</scientifictitle>
    <utrn>U1111-1118-3129</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cognition</healthcondition>
    <healthcondition>Hyperchloremic acidosis</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Studies of the normal brain and nervous system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Studies of normal psychology, cognitive function and behaviour</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>0.9% saline (Baxter Healthcare, Sydney NSW), 30 ml / kg , intravenously over 1 hr. At least 24 hours washout before cross-over.</interventions>
    <comparator>Plasmalyte (Baxter Healthcare, Sydney NSW), 30 ml / kg , intravenously over 1 hr, cross-over.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reaction Time Index
Previously reported test:
VELISSARIS, S. L., WILSON, S. J., NEWTON, M. R., BERKOVIC, S. F. &amp; SALING, M. M. (2009) Cognitive complaints after a first seizure in adulthood: Influence of psychological adjustment. Epilepsia, 50, 1012-21.</outcome>
      <timepoint>Immediately before and immediately after  infusions.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Differences in Wechsler Adult Intelligence Scale (3rd Edition) (WAIS-III):  Processing Speed Index (PSI)</outcome>
      <timepoint>Immediately after infusions only.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The A/B neuropsychological assessment schedule (ABNAS): subjective cognition measure, modified to the previous hour</outcome>
      <timepoint>Immediately after infusions only.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Profile of Mood State (POMS)</outcome>
      <timepoint>Immediately after infusions only.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Chemistry: pH, standard base-excess, chloride, sodium, sodium chloride difference (Na-Cl), and measured Strong ion difference: (Na+K-Cl-Lact)</outcome>
      <timepoint>Immediately before and after infusions.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy adults not requiring any daily medication other than the contraceptive pill</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1.	Decline to participate.
2.	Pregnant women
3.	Aged less than 18 years.
4.	Aged more than 60 years
5.	Require any daily medication other than the contraceptive pill.
6. Heart disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>25 particpants invited to volunteer for randomized cross-over trial. Alocation to first arm of cross over in opaque sealed envelopes.</concealment>
    <sequence>Table of random numbers of 0 and 1 for first infusion of cross-over</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>27/05/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>David Story</primarysponsorname>
    <primarysponsoraddress>Dept of Anaesthesia Austin Hospital, Studley Rd, Heidelberg,Vic, 3084</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Dept of Anaesthesia Research Fund</fundingname>
      <fundingaddress>Dept of Anaesthesia Austin Hospital, Studley Rd, Heidelberg,Vic, 3084</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Sarah Wilson</othercollaboratorname>
      <othercollaboratoraddress>Dept of Neuropsychology, Austin Hospital, Studley Rd, Heidelberg,Vic, 3084</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Laurence Weinberg</othercollaboratorname>
      <othercollaboratoraddress>Dept of Anaesthesia Austin Hospital, Studley Rd, Heidelberg,Vic, 3084</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Rinaldo Bellomo</othercollaboratorname>
      <othercollaboratoraddress>Dept of ICU, Austin Hospital, Studley Rd, Heidelberg,Vic, 3084</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Intravenous crytsalloid fluids are one of the mainstays of in-hospital patient treatment with fluid intervention
being ubiquitous for surgical and critical care patients. Cognitive changes such as a perceived difficulty in
abstract thinking or mental arithmetic has been reported in subjects exposed to a commonly prescribed
crystalloid solution - Normal Saline (0.9%). The postulated mechanism for the altered cognition is unclear
but could be a result of NS 0.9% induced hyperchloraemia or NS 0.9% induced acidaemia (normal anion
gap metabolic acidosis) that frequently occurs following saline administration. No study has attempted to
formally investigate cognitive changes after the administration of saline or other commonly administered
crystalloid solutions. Plasmalyte solution is a frequently used crystalloid solution with similiar properties to
saline. However it is a more physiological and balanced crystalloid solution compared to saline as it has a
significantly lower chloride concentration and physiochemical profile similar to normal plasma.
Study hypothesis: Is normal saline associated with greater cognitive changes than Plasmalyte in healthy
volunteers?</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Ethics Unit
Austin Hospital Studley Rd Heidelberg</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>18/01/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof David Story</name>
      <address>Dept of Anaesthesia
Austin Hospital
Studley Rd, Heidelberg, Vic, 3084</address>
      <phone>61-3-9496 3800</phone>
      <fax />
      <email>David.Story@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof David Story</name>
      <address>Dept of Anaesthesia
Austin Hospital
Studley Rd, Heidelberg, Vic, 3084</address>
      <phone>61-3-9496 3800</phone>
      <fax />
      <email>David.Story@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof David Story</name>
      <address>Dept of Anaesthesia
Austin Hospital
Studley Rd, Heidelberg, Vic, 3084</address>
      <phone>61-3-9496 3800</phone>
      <fax />
      <email>David.Story@austin.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>